Selvedge Venture

Overview

Selvedge Venture is a London-based venture capital firm investing in early-stage companies focused on age-related medical conditions. The firm specializes in platform technologies and interventions aimed at transforming patient outcomes in areas such as Metabolic Syndrome, Oncology, and Neurodegeneration. Founded by professionals from the venture capital, healthcare, life science, and pharmaceutical industries, Selvedge Venture is backed by family offices and high-net-worth individuals. The firm's investment strategy targets early-stage companies, including Pre-Seed, Seed, and Series A stages, with a focus on sectors like Biotechnology, Artificial Intelligence, Health Care, Medical Devices, Life Sciences, Pharmaceuticals, Therapeutics, Biopharma, and Bioinformatics. Selvedge Venture has a history of active investments, with notable recent deals including a $3 million investment in Mesh Bio in October 2023. Selvedge Venture's portfolio companies are involved in diverse areas such as neural interfaces and therapeutics development, weight loss solutions, AI-driven clinical patient triage, liver transplant and drug testing, healthcare fintech, chemistry platforms, transdermal drug delivery, and AI-enabled cell therapy discovery. The firm's approach emphasizes future-proof impact investing, aiming to alleviate the healthcare burden caused by age-related medical conditions through innovative solutions. Selvedge Venture is registered in England and Wales with company number OC431669 and operates as an appointed representative of Panima Capital Management Limited, which is authorized and regulated by the Financial Conduct Authority. The firm is committed to respecting and protecting privacy, collecting and using limited personal information to manage relationships with investors and professional contacts. Please note that investing in venture capital involves high risks, and investors should be prepared to lose all the money they invest. The information provided is intended solely for professional investors, as defined under the Markets in Financial Instruments Directive II (MiFID II).

Investment Focus

• Professional investors as defined under MiFID II

Portfolio Companies